In the high-stakes world of pharmaceutical development, not all clinical successes translate to commercial triumphs, a reality starkly illustrated when Amgen announced it was terminating its partnership with Kyowa Kirin for the eczema drug rocatinlimab, handing back the rights to a once-promising
Today we are speaking with Ivan Kairatov, a biopharma expert with deep insight into the intersection of technology and research in mental healthcare. We will be exploring the UK's ambitious new Mental Health Goals programme, a transformative initiative poised to reshape how we understand and treat
For the millions of people living with Parkinson's disease, the diagnosis often arrives like a conclusion to a story whose beginning was missed, confirming a devastating neurological decline that has been silently underway for years. The core challenge in managing this progressive disorder, which
A strategic maneuver from the titan of mRNA vaccine technology has shifted a potentially life-changing therapy for a rare disease into the hands of a specialized pharmaceutical firm, signaling a significant recalibration of priorities for both companies. In a deal that highlights the complex
A groundbreaking personalized cancer therapy that essentially teaches a patient's own immune system how to recognize and destroy their specific tumor has delivered remarkable results in its initial human trial, signaling a potential new era in the fight against advanced solid tumors. This
A recent clinical trial has successfully demonstrated that treating a rare and aggressive skin cancer with immunotherapy before surgery can completely eliminate tumors in the majority of patients, heralding a profound shift in how this formidable disease is managed. The groundbreaking research,
